Because compensatory mechanisms exist in cells for loss of CDK2/cyclin E activity48, inhibition of CDK12 and/or CDK13 may be a more effective approach to treat deadly cancers such as high-grade serous ovarian carcinoma. The gene discussed is CCNE1; the disease is ovarian serous carcinoma.